Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:48:56 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:VKTX from 2025-02-07 to 2026-02-06 - 23 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-02-04 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
2026-01-12 07:00U:VKTXNews ReleaseViking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
2026-01-08 07:00U:VKTXNews ReleaseViking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
2026-01-07 07:00U:VKTXNews ReleaseViking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
2026-01-05 16:03U:VKTXNews ReleaseViking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-11-25 16:05U:VKTXNews ReleaseViking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
2025-11-19 02:55U:VKTXNews ReleaseViking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
2025-11-06 07:05U:VKTXNews ReleaseViking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek(TM) 2025
2025-11-04 16:05U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2025-10-29 16:05U:VKTXNews ReleaseViking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek(TM) 2025
2025-10-22 16:05U:VKTXNews ReleaseViking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-10-21 07:05U:VKTXNews ReleaseViking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
2025-10-15 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025
2025-08-28 16:30U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2025-08-19 07:05U:VKTXNews ReleaseViking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
2025-07-23 16:05U:VKTXNews ReleaseViking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025-07-16 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025
2025-06-25 07:03U:VKTXNews ReleaseViking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
2025-04-23 16:05U:VKTXNews ReleaseViking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
2025-04-16 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025
2025-03-26 07:05U:VKTXNews ReleaseViking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
2025-03-11 07:03U:VKTXNews ReleaseViking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
2025-03-04 16:05U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences